STARKS DANIEL J 4
4 · ABBOTT LABORATORIES · Filed May 2, 2023
Insider Transaction Report
Form 4
STARKS DANIEL J
Director
Transactions
- Sale
Common shares without par value
2023-05-02$111.75/sh−3,452$385,761→ 6,825,316 total - Award
Option (right to buy)
2023-04-28+8,136→ 8,136 totalExercise: $110.12From: 2023-04-28Exp: 2033-04-27→ Common Shares (8,136 underlying) - Award
Common shares without par value
2023-04-28+1,816→ 6,875,316 total - Sale
Common shares without par value
2023-05-02$110.97/sh−46,548$5,165,432→ 6,828,768 total
Holdings
- 258(indirect: By Trust)
Common shares without par value
Footnotes (5)
- [F1]These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.51 to $111.50, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.58 to $111.90, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F4]Held in the Alynne Starks 2012 Irrevocable Trust. The reporting person is the sole trustee of the trust.
- [F5]Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.